Evidence map›Paper›PMID 26009836›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2015

Implementation and Operational Research: Correlates of Adherence and Treatment Failure Among Kenyan Patients on Long-term Highly Active Antiretroviral Therapy.

Washingtone Ochieng, Rose C Kitawi, Timothy J Nzomo, Ruth S Mwatelah, Maureen J Kimulwo, Dorothy J Ochieng, Joyceline Kinyua, Nancy Lagat, Kevin O Onyango, Raphael M Lwembe and 4 more

Open access · greenAbstract readMulticenter Study
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Washingtone Ochieng*Center for Research in Therapeutic Sciences and the Institute of Healthcare Management, Strathmore University, Nairobi, Kenya; †Kenya Medical Research Institute, Nairobi, Kenya; ‡Institute of Tropical Medicine and Infectious Diseases at JKUAT, Nairobi, Kenya; §MCPHS University, Worcester, MA; ‖Center for Global Public Health, Tufts University School of Medicine, Boston, MA; and ¶African Centre for Clinical Trials, Nairobi, Kenya.
Rose C Kitawi
Timothy J Nzomo
Ruth S Mwatelah
Maureen J Kimulwo
Dorothy J Ochieng
Joyceline Kinyua
Nancy Lagat
Kevin O Onyango
Raphael M Lwembe
Mkaya Mwamburi
Bernhards R Ogutu
Florence A Oloo
Rashid Aman
Kenya Medical Research Institute · KEStrathmore University · KEWellcome Trust · GB

Funding

Wellcome Trust 080883KOKWAROWellcome Trust WT080883
6 · The paper itself

Abstract

backgroundUniversal access to highly active antiretroviral therapy (HAART) is still elusive in most developing nations. We asked whether peer support influenced adherence and treatment outcome and if a single viral load (VL) could define treatment failure in a resource-limited setting.

methodsA multicenter longitudinal and cross-sectional survey of VL, CD4 T cells, and adherence in 546 patients receiving HAART for up to 228 months. VL and CD4 counts were determined using m2000 Abbott RealTime HIV-1 assay and FACS counters, respectively. Adherence was assessed based on pill count and on self-report.

resultsOf the patients, 55.8%, 22.2%, and 22% had good, fair, and poor adherence, respectively. Adherence, peer support, and regimen, but not HIV disclosure, age, or gender, independently correlated with VL and durability of treatment in a multivariate analysis (P < 0.001). Treatment failure was 35.9% using sequential VL but ranged between 27% and 35% using alternate single VL cross-sectional definitions. More patients failed stavudine (41.2%) than zidovudine (37.4%) or tenofovir (28.8%, P = 0.043) treatment arms. Peer support correlated positively with adherence (χ(2), P < 0.001), with nonadherence being highest in the stavudine arm. VL before the time of regimen switch was comparable between patients switching and not switching treatment. Moreover, 36% of those switching still failed the second-line regimen.

conclusionWeak adherence support and inaccessible VL testing threaten to compromise the success of HAART scale-up in Kenya. To hasten antiretroviral therapy monitoring and decision making, we suggest strengthening patient-focused adherence programs, optimizing and aligning regimen to WHO standards, and a single point-of-care VL testing when multiple tests are unavailable.

Indexed as

Medication AdherenceAdolescentAdultAgedAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveChildChild, PreschoolCohort StudiesCross-Sectional StudiesDrug MonitoringFemaleHealth Services AccessibilityHIV InfectionsHumansKenyaAnti-Retroviral Agents

Identifiers

PMID26009836
PMCPMC4445604
OpenAlexW1483859993

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.